Postleukemic dysmyelopoiesis

Kathy Foucar, William P. Vaughan, James Olen Armitage, Shivanand Patil, Fred Dick, Judith E. Karp

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The morphologic and clinical features of four patients who developed significant bone marrow and blood dyspoiesis after successful chemotherapy for acute nonlymphocytic leukemia (ANLL) are described. This postleukemic dyspoiesis developed 1‐6 months after leukemia induction therapy and persisted for 5‐20 months in a relatively stable state. This period of prolonged dyspoiesis was not associated with rising myeloblast counts or clinical evidence of relapse. Dyspoietic abnormalities developed while two patients were receiving maintenance chemotherapy; the other two patients received no maintenance therapy. The dyspoietic changes in these four patients greatly exceeded those noted in a control group of ANLL patients on maintenance chemotherapy. The morphologic features of postleukemic dysmyelopoiesis were similar to those described in preleukemic dysmyelopoietic disorders. Erythroid abnormalities included hyperplasia with ring sideroblasts, megalobalstic changes, and cytoplasmic PAS reactivity. Myeloid abnormalities consisted of left‐shifted granulopoiesis with hyper‐ and hyposegmentation; megakaryocytic abnormalities included hyperplasia with a predominance of hypolobulated forms. Three of the four patients eventually suffered relapse and have died. The fourth patient died of sepsis after 20 months of pancytopenia and hysmyelopoiesis. Theories to explain the development of postleukemic dysmyelopoiesis are presented which emphasize the possibility of drug‐induced leukemia cell differentiation. Cytogenetic studies will be necessary to establish any relationship between ANLL and the subsequent postleukemic dysmyelopoiesis.

Original languageEnglish (US)
Pages (from-to)321-334
Number of pages14
JournalAmerican Journal of Hematology
Volume15
Issue number4
DOIs
StatePublished - Jan 1 1983

Fingerprint

Maintenance Chemotherapy
Acute Myeloid Leukemia
Hyperplasia
Leukemia
Recurrence
Granulocyte Precursor Cells
Pancytopenia
Cytogenetics
Cell Differentiation
Sepsis
Bone Marrow
Drug Therapy
Control Groups
Therapeutics

Keywords

  • dysmyelopoiesis
  • myelodysplasia
  • postleukemic changes

ASJC Scopus subject areas

  • Hematology

Cite this

Foucar, K., Vaughan, W. P., Armitage, J. O., Patil, S., Dick, F., & Karp, J. E. (1983). Postleukemic dysmyelopoiesis. American Journal of Hematology, 15(4), 321-334. https://doi.org/10.1002/ajh.2830150403

Postleukemic dysmyelopoiesis. / Foucar, Kathy; Vaughan, William P.; Armitage, James Olen; Patil, Shivanand; Dick, Fred; Karp, Judith E.

In: American Journal of Hematology, Vol. 15, No. 4, 01.01.1983, p. 321-334.

Research output: Contribution to journalArticle

Foucar, K, Vaughan, WP, Armitage, JO, Patil, S, Dick, F & Karp, JE 1983, 'Postleukemic dysmyelopoiesis', American Journal of Hematology, vol. 15, no. 4, pp. 321-334. https://doi.org/10.1002/ajh.2830150403
Foucar K, Vaughan WP, Armitage JO, Patil S, Dick F, Karp JE. Postleukemic dysmyelopoiesis. American Journal of Hematology. 1983 Jan 1;15(4):321-334. https://doi.org/10.1002/ajh.2830150403
Foucar, Kathy ; Vaughan, William P. ; Armitage, James Olen ; Patil, Shivanand ; Dick, Fred ; Karp, Judith E. / Postleukemic dysmyelopoiesis. In: American Journal of Hematology. 1983 ; Vol. 15, No. 4. pp. 321-334.
@article{aba63f634faa44c68aabb59912ca0532,
title = "Postleukemic dysmyelopoiesis",
abstract = "The morphologic and clinical features of four patients who developed significant bone marrow and blood dyspoiesis after successful chemotherapy for acute nonlymphocytic leukemia (ANLL) are described. This postleukemic dyspoiesis developed 1‐6 months after leukemia induction therapy and persisted for 5‐20 months in a relatively stable state. This period of prolonged dyspoiesis was not associated with rising myeloblast counts or clinical evidence of relapse. Dyspoietic abnormalities developed while two patients were receiving maintenance chemotherapy; the other two patients received no maintenance therapy. The dyspoietic changes in these four patients greatly exceeded those noted in a control group of ANLL patients on maintenance chemotherapy. The morphologic features of postleukemic dysmyelopoiesis were similar to those described in preleukemic dysmyelopoietic disorders. Erythroid abnormalities included hyperplasia with ring sideroblasts, megalobalstic changes, and cytoplasmic PAS reactivity. Myeloid abnormalities consisted of left‐shifted granulopoiesis with hyper‐ and hyposegmentation; megakaryocytic abnormalities included hyperplasia with a predominance of hypolobulated forms. Three of the four patients eventually suffered relapse and have died. The fourth patient died of sepsis after 20 months of pancytopenia and hysmyelopoiesis. Theories to explain the development of postleukemic dysmyelopoiesis are presented which emphasize the possibility of drug‐induced leukemia cell differentiation. Cytogenetic studies will be necessary to establish any relationship between ANLL and the subsequent postleukemic dysmyelopoiesis.",
keywords = "dysmyelopoiesis, myelodysplasia, postleukemic changes",
author = "Kathy Foucar and Vaughan, {William P.} and Armitage, {James Olen} and Shivanand Patil and Fred Dick and Karp, {Judith E.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/ajh.2830150403",
language = "English (US)",
volume = "15",
pages = "321--334",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Postleukemic dysmyelopoiesis

AU - Foucar, Kathy

AU - Vaughan, William P.

AU - Armitage, James Olen

AU - Patil, Shivanand

AU - Dick, Fred

AU - Karp, Judith E.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - The morphologic and clinical features of four patients who developed significant bone marrow and blood dyspoiesis after successful chemotherapy for acute nonlymphocytic leukemia (ANLL) are described. This postleukemic dyspoiesis developed 1‐6 months after leukemia induction therapy and persisted for 5‐20 months in a relatively stable state. This period of prolonged dyspoiesis was not associated with rising myeloblast counts or clinical evidence of relapse. Dyspoietic abnormalities developed while two patients were receiving maintenance chemotherapy; the other two patients received no maintenance therapy. The dyspoietic changes in these four patients greatly exceeded those noted in a control group of ANLL patients on maintenance chemotherapy. The morphologic features of postleukemic dysmyelopoiesis were similar to those described in preleukemic dysmyelopoietic disorders. Erythroid abnormalities included hyperplasia with ring sideroblasts, megalobalstic changes, and cytoplasmic PAS reactivity. Myeloid abnormalities consisted of left‐shifted granulopoiesis with hyper‐ and hyposegmentation; megakaryocytic abnormalities included hyperplasia with a predominance of hypolobulated forms. Three of the four patients eventually suffered relapse and have died. The fourth patient died of sepsis after 20 months of pancytopenia and hysmyelopoiesis. Theories to explain the development of postleukemic dysmyelopoiesis are presented which emphasize the possibility of drug‐induced leukemia cell differentiation. Cytogenetic studies will be necessary to establish any relationship between ANLL and the subsequent postleukemic dysmyelopoiesis.

AB - The morphologic and clinical features of four patients who developed significant bone marrow and blood dyspoiesis after successful chemotherapy for acute nonlymphocytic leukemia (ANLL) are described. This postleukemic dyspoiesis developed 1‐6 months after leukemia induction therapy and persisted for 5‐20 months in a relatively stable state. This period of prolonged dyspoiesis was not associated with rising myeloblast counts or clinical evidence of relapse. Dyspoietic abnormalities developed while two patients were receiving maintenance chemotherapy; the other two patients received no maintenance therapy. The dyspoietic changes in these four patients greatly exceeded those noted in a control group of ANLL patients on maintenance chemotherapy. The morphologic features of postleukemic dysmyelopoiesis were similar to those described in preleukemic dysmyelopoietic disorders. Erythroid abnormalities included hyperplasia with ring sideroblasts, megalobalstic changes, and cytoplasmic PAS reactivity. Myeloid abnormalities consisted of left‐shifted granulopoiesis with hyper‐ and hyposegmentation; megakaryocytic abnormalities included hyperplasia with a predominance of hypolobulated forms. Three of the four patients eventually suffered relapse and have died. The fourth patient died of sepsis after 20 months of pancytopenia and hysmyelopoiesis. Theories to explain the development of postleukemic dysmyelopoiesis are presented which emphasize the possibility of drug‐induced leukemia cell differentiation. Cytogenetic studies will be necessary to establish any relationship between ANLL and the subsequent postleukemic dysmyelopoiesis.

KW - dysmyelopoiesis

KW - myelodysplasia

KW - postleukemic changes

UR - http://www.scopus.com/inward/record.url?scp=0021083396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021083396&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830150403

DO - 10.1002/ajh.2830150403

M3 - Article

C2 - 6650493

AN - SCOPUS:0021083396

VL - 15

SP - 321

EP - 334

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -